Logo for Savara Inc

Savara Inc Investor Relations Material

Latest events

Logo for Savara Inc

Q3 2024

12 Nov, 2024
Logo for Savara Inc

Q4 2023

7 Mar, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Savara Inc

Access all reports
Savara Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company's main focus is on advancing its lead product candidate, molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). In addition to molgramostim, Savara is also developing AeroVanc, an inhaled vancomycin aimed at treating methicillin-resistant Staphylococcus aureus (MRSA) lung infections in cystic fibrosis patients. Savara is headquartered in Austin, Texas, and its shares are listed on the NASDAQ.